Cytogen Corp. on Thursday said it has won market approval inthe United Kingdom and the Netherlands for its monoclonalantibody-based cancer imaging agent for colorectal cancer.

The company's OncoScint CR103 had received approvals inOctober for Germany and Luxembourg. OncoScint will be sold inEurope through EuroCetus, Cytogen Corp.'s exclusive marketingpartner.

The company estimates that 150,000 new cases of colorectalcancer were diagnosed in 1990 in Western Europe, and thatcountries in which OncoScint has been approved account for 60percent of the cases.

The Princeton, N.J., company has filed a product licenseapplication in the United States.

Cytogen stock (NASDAQ:CYTO) closed unchanged at $17.88.

(c) 1997 American Health Consultants. All rights reserved.